Even though palliative care is only for pain management and symptoms of an illness and not curative, it’s still an important part of the treatment regimen for those suffering from any illness, especially mesothelioma. Pain associated with mesothelioma increases as the disease increases with severity. The most common pain experienced[…]
From the blog
Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer
TC-210 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex.
This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently determine an overall response rate in patients with advanced mesothelin-expressing cancers.
Mesothelioma Patient Survival Potentially Doubles with Targeted Radiotherapy
Radiotherapy, also known as radiation therapy, is a type of cancer treatment that uses ionizing radiation to kill cancer cells by damaging the cell’s DNA. It can be used as either a curative or palliative treatment and is often used alongside chemotherapy, either before, during, or after. Radiotherapy can be[…]
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid tumors.
Survival Factors for Mesothelioma Highlighted by University of Pittsburgh Medical Center
According to GLOBOCAN 2018 statistics, each year there are 30,443 mesothelioma cases worldwide, and of those 30,443, 25,576 pass away. With close to 85 percent of those diagnosed succumbing to the disease, mesothelioma remains one of the most deadly cancers as there is no cure. However, surviving a mesothelioma diagnosis[…]
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.
Phase III Clinical Trial for Mesothelioma Available in 50 Locations Across the Globe
A Phase III clinical trial is now underway in the pivotal study of interferon alfa-2b gene therapy in pleural mesothelioma. After promising results from the Phase II clinical trial, scientists and researchers are hopeful they are just one step away from FDA approval for this cancer treatment that is over[…]
Nomogram May More Accurately Predict Mesothelioma Survival
Predicting pleural mesothelioma survival is a difficult task, as a number of factors are needed to make an accurate calculation. Currently, the TNM Staging system in place as one of the ways to predict life-expectancy and survival after a mesothelioma patient has had surgery. However, researchers from Peking University in[…]
Asbestos Awareness Week: April 1 – April 7, 2019
Asbestos Awareness Week starts today. The Asbestos Disease Awareness Organization (ADAO) is kicking off this global campaign of education and awareness about the risks of asbestos and the need for a ban with a candlelight vigil. Throughout the week, they’ll be presenting information from doctors, activists, and victims of asbestos[…]
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
MESOTIP is a randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma In this study, patients in the experimental arm will be treated by 4 PIPAC (Cisplatine+Doxorubicine) alternating with 6 cycles of standard intravenous chemotherapy (Cisplatine+Pemetrexed).
